Opinion|Videos|December 3, 2024
Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- PIRA represents MS progression without clinical relapses, impacting patients' quality of life by contributing to disability accumulation.
- Unlike RAW, PIRA reflects insidious progression, often undetected by traditional relapse-focused assessments.
Panelists discuss how progression independent of relapse activity (PIRA) in multiple sclerosis (MS) represents continuous neurological decline unrelated to inflammatory events, distinct from relapse-associated worsening (RAW). Recent ECTRIMS 2024 presentations emphasized standardized evaluation methods to better understand disease progression and improve patient management strategies.
Advertisement
Video content above is prompted by the following:
- Cognition and PIRA in MS have received a lot of attention in recent years.
- Please provide an overview of PIRA and its potential impact on a patient’s quality of life.
- How is PIRA different from RAW?
- How is PIRA evaluated? Discuss presentations from ECTRIMS 2024 by Muller and others about standardization of PIRA evaluation and why it might matter.
Advertisement
Related to this article
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Terrie Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
2
Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD
3
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
4
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
5